Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:organic sulfate salt
go back to main search page
Accession:CHEBI:51337 term browser browse the term
Synonyms:related_synonym: organic sulfate salts



show annotations for term's descendants           Sort by:
5-methylphenazinium methyl sulfate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G G6PD glucose-6-phosphate dehydrogenase increases activity EXP Methylphenazonium Methosulfate results in increased activity of G6PD protein CTD PMID:1901343 NCBI chr  X:154,531,390...154,547,569
Ensembl chr  X:154,517,825...154,547,572
JBrowse link
G PGD phosphogluconate dehydrogenase increases activity EXP Methylphenazonium Methosulfate results in increased activity of PGD protein CTD PMID:1901343 NCBI chr 1:10,399,064...10,420,511
Ensembl chr 1:10,398,592...10,420,511
JBrowse link
atazanavir sulfate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABCB1 ATP binding cassette subfamily B member 1 increases transport
multiple interactions
EXP ABCB1 protein results in increased transport of Atazanavir Sulfate
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCB1 mRNA
CTD PMID:29859254 PMID:33819548 NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323
JBrowse link
G ABCB11 ATP binding cassette subfamily B member 11 decreases activity
multiple interactions
EXP Atazanavir Sulfate results in decreased activity of ABCB11 protein
Atazanavir Sulfate inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]
CTD PMID:24014644 NCBI chr 2:168,915,390...169,031,324
Ensembl chr 2:168,915,498...169,031,324
JBrowse link
G ABCB4 ATP binding cassette subfamily B member 4 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCB4 mRNA CTD PMID:33819548 NCBI chr 7:87,365,896...87,476,027
Ensembl chr 7:87,401,696...87,480,435
JBrowse link
G ABCC2 ATP binding cassette subfamily C member 2 decreases expression EXP Atazanavir Sulfate results in decreased expression of ABCC2 mRNA CTD PMID:32152650 NCBI chr10:99,782,640...99,852,594
Ensembl chr10:99,782,640...99,852,594
JBrowse link
G ABCC3 ATP binding cassette subfamily C member 3 decreases expression EXP Atazanavir Sulfate results in decreased expression of ABCC3 mRNA CTD PMID:32152650 NCBI chr17:50,634,881...50,692,253
Ensembl chr17:50,634,777...50,692,253
JBrowse link
G ABCG2 ATP binding cassette subfamily G member 2 (JR blood group) multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of ABCG2 mRNA CTD PMID:33819548 NCBI chr 4:88,090,264...88,231,626
Ensembl chr 4:88,090,150...88,231,628
JBrowse link
G ABCG5 ATP binding cassette subfamily G member 5 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCG5 mRNA CTD PMID:33819548 NCBI chr 2:43,806,211...43,839,231
Ensembl chr 2:43,812,472...43,838,865
JBrowse link
G ABCG8 ATP binding cassette subfamily G member 8 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCG8 mRNA CTD PMID:33819548 NCBI chr 2:43,838,971...43,882,988
Ensembl chr 2:43,831,942...43,882,988
JBrowse link
G ACSL1 acyl-CoA synthetase long chain family member 1 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ACSL1 mRNA CTD PMID:33819548 NCBI chr 4:184,755,595...184,826,594
Ensembl chr 4:184,755,595...184,826,818
JBrowse link
G ADGRG1 adhesion G protein-coupled receptor G1 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of ADGRG1 mRNA CTD PMID:33819548 NCBI chr16:57,619,738...57,665,567
Ensembl chr16:57,610,652...57,665,580
JBrowse link
G ADH1C alcohol dehydrogenase 1C (class I), gamma polypeptide multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ADH1C mRNA CTD PMID:33819548 NCBI chr 4:99,336,497...99,352,746
Ensembl chr 4:99,336,497...99,352,746
JBrowse link
G ADH4 alcohol dehydrogenase 4 (class II), pi polypeptide multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ADH4 mRNA CTD PMID:33819548 NCBI chr 4:99,123,658...99,144,297
Ensembl chr 4:99,123,657...99,157,792
JBrowse link
G ADH6 alcohol dehydrogenase 6 (class V) multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ADH6 mRNA CTD PMID:33819548 NCBI chr 4:99,202,639...99,219,246
Ensembl chr 4:99,202,638...99,219,537
JBrowse link
G AKR1C4 aldo-keto reductase family 1 member C4 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of AKR1C4 mRNA CTD PMID:33819548 NCBI chr10:5,196,837...5,218,949
Ensembl chr10:5,195,462...5,218,949
JBrowse link
G AKR1D1 aldo-keto reductase family 1 member D1 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of AKR1D1 mRNA CTD PMID:33819548 NCBI chr 7:138,076,459...138,118,305
Ensembl chr 7:138,002,324...138,118,305
JBrowse link
G AKR7A3 aldo-keto reductase family 7 member A3 decreases expression
multiple interactions
EXP Atazanavir Sulfate results in decreased expression of AKR7A3 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA
CTD PMID:32152650 NCBI chr 1:19,274,229...19,288,770
Ensembl chr 1:19,282,573...19,288,770
JBrowse link
G ALB albumin affects binding
multiple interactions
EXP Atazanavir Sulfate binds to ALB protein
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ALB mRNA
CTD PMID:15814459 PMID:16336266 PMID:33819548 NCBI chr 4:73,404,287...73,421,482
Ensembl chr 4:73,397,114...73,421,482
JBrowse link
G ALPP alkaline phosphatase, placental multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ALPP mRNA CTD PMID:33819548 NCBI chr 2:232,378,751...232,382,889
Ensembl chr 2:232,378,724...232,382,889
JBrowse link
G AMPD3 adenosine monophosphate deaminase 3 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of AMPD3 mRNA CTD PMID:33819548 NCBI chr11:10,450,388...10,507,579
Ensembl chr11:10,308,313...10,507,579
JBrowse link
G APOA1 apolipoprotein A1 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of APOA1 mRNA CTD PMID:33819548 NCBI chr11:116,835,751...116,837,622
Ensembl chr11:116,835,751...116,837,622
JBrowse link
G ATF4 activating transcription factor 4 multiple interactions
increases expression
EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA
Atazanavir Sulfate results in increased expression of ATF4 mRNA
CTD PMID:32152650 NCBI chr22:39,520,559...39,522,686
Ensembl chr22:39,519,695...39,522,686
JBrowse link
G ATF6 activating transcription factor 6 multiple interactions
increases expression
EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA
Atazanavir Sulfate results in increased expression of ATF6 mRNA
CTD PMID:32152650 NCBI chr 1:161,766,320...161,964,070
Ensembl chr 1:161,766,298...161,977,574
JBrowse link
G ATG7 autophagy related 7 increases expression
multiple interactions
EXP Atazanavir Sulfate results in increased expression of ATG7 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA
CTD PMID:32152650 NCBI chr 3:11,272,397...11,576,353
Ensembl chr 3:11,272,309...11,557,665
JBrowse link
G ATP8B1 ATPase phospholipid transporting 8B1 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ATP8B1 mRNA CTD PMID:33819548 NCBI chr18:57,646,426...57,803,315
Ensembl chr18:57,646,426...57,803,315
JBrowse link
G BAAT bile acid-CoA:amino acid N-acyltransferase multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of BAAT mRNA CTD PMID:33819548 NCBI chr 9:101,360,417...101,385,006
Ensembl chr 9:101,354,182...101,385,400
JBrowse link
G BCL2L1 BCL2 like 1 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of BCL2L1 mRNA CTD PMID:33819548 NCBI chr20:31,664,452...31,723,963
Ensembl chr20:31,664,452...31,723,989
JBrowse link
G CAT catalase multiple interactions
decreases expression
EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA
Atazanavir Sulfate results in decreased expression of CAT mRNA
CTD PMID:32152650 NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
JBrowse link
G CCL2 C-C motif chemokine ligand 2 increases expression EXP Atazanavir Sulfate results in increased expression of CCL2 protein CTD PMID:17668557 NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,274...34,257,208
JBrowse link
G CCL3 C-C motif chemokine ligand 3 increases expression EXP Atazanavir Sulfate results in increased expression of CCL3 protein CTD PMID:17668557 NCBI chr17:36,088,256...36,090,143
Ensembl chr17:36,088,256...36,090,169
JBrowse link
G CHI3L1 chitinase 3 like 1 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CHI3L1 mRNA CTD PMID:33819548 NCBI chr 1:203,178,931...203,186,704
Ensembl chr 1:203,178,931...203,186,704
JBrowse link
G CSF1 colony stimulating factor 1 multiple interactions
increases expression
EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA
Atazanavir Sulfate results in increased expression of CSF1 mRNA
CTD PMID:32152650 NCBI chr 1:109,910,506...109,930,992
Ensembl chr 1:109,910,242...109,930,992
JBrowse link
G CTNNB1 catenin beta 1 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CTNNB1 mRNA CTD PMID:33819548 NCBI chr 3:41,199,505...41,240,443
Ensembl chr 3:41,194,741...41,260,096
JBrowse link
G CTTN cortactin multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of CTTN mRNA CTD PMID:33819548 NCBI chr11:70,398,529...70,436,575
Ensembl chr11:70,398,404...70,436,584
JBrowse link
G CXCL8 C-X-C motif chemokine ligand 8 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of CXCL8 mRNA CTD PMID:33819548 NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716
JBrowse link
G CYLD CYLD lysine 63 deubiquitinase multiple interactions
increases expression
EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA
Atazanavir Sulfate results in increased expression of CYLD mRNA
CTD PMID:32152650 NCBI chr16:50,742,086...50,801,935
Ensembl chr16:50,742,050...50,801,935
JBrowse link
G CYP1A2 cytochrome P450 family 1 subfamily A member 2 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP1A2 mRNA CTD PMID:33819548 NCBI chr15:74,748,845...74,756,607
Ensembl chr15:74,748,845...74,756,607
JBrowse link
G CYP27A1 cytochrome P450 family 27 subfamily A member 1 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP27A1 mRNA CTD PMID:33819548 NCBI chr 2:218,782,147...218,815,293
Ensembl chr 2:218,781,749...218,815,293
JBrowse link
G CYP2A6 cytochrome P450 family 2 subfamily A member 6 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP2A6 mRNA CTD PMID:33819548 NCBI chr19:40,843,541...40,850,447
Ensembl chr19:40,843,541...40,850,447
JBrowse link
G CYP2B6 cytochrome P450 family 2 subfamily B member 6 decreases expression
multiple interactions
EXP Atazanavir Sulfate results in decreased expression of CYP2B6 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA
CTD PMID:32152650 NCBI chr19:40,991,282...41,018,398
Ensembl chr19:40,991,282...41,018,398
JBrowse link
G CYP2C18 cytochrome P450 family 2 subfamily C member 18 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP2C18 mRNA CTD PMID:33819548 NCBI chr10:94,683,729...94,736,190
Ensembl chr10:94,683,729...94,736,190
JBrowse link
G CYP2C19 cytochrome P450 family 2 subfamily C member 19 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP2C19 mRNA CTD PMID:33819548 NCBI chr10:94,762,681...94,855,547
Ensembl chr10:94,762,681...94,855,547
JBrowse link
G CYP2C9 cytochrome P450 family 2 subfamily C member 9 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP2C9 mRNA CTD PMID:33819548 NCBI chr10:94,938,658...94,990,091
Ensembl chr10:94,938,658...94,990,091
JBrowse link
G CYP3A4 cytochrome P450 family 3 subfamily A member 4 multiple interactions
decreases expression
EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA
Atazanavir Sulfate results in decreased expression of CYP3A4 mRNA
CTD PMID:32152650 NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248
JBrowse link
G CYP3A5 cytochrome P450 family 3 subfamily A member 5 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP3A5 mRNA CTD PMID:33819548 NCBI chr 7:99,648,194...99,679,996
Ensembl chr 7:99,648,194...99,679,996
JBrowse link
G CYP7A1 cytochrome P450 family 7 subfamily A member 1 multiple interactions
decreases expression
EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA
Atazanavir Sulfate results in decreased expression of CYP7A1 mRNA
CTD PMID:32152650 NCBI chr 8:58,490,178...58,500,163
Ensembl chr 8:58,490,178...58,500,163
JBrowse link
G CYP7B1 cytochrome P450 family 7 subfamily B member 1 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP7B1 mRNA CTD PMID:33819548 NCBI chr 8:64,586,575...64,798,737
Ensembl chr 8:64,587,763...64,798,737
JBrowse link
G CYP8B1 cytochrome P450 family 8 subfamily B member 1 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP8B1 mRNA CTD PMID:33819548 NCBI chr 3:42,872,192...42,875,879
Ensembl chr 3:42,856,005...42,875,898
JBrowse link
G DDIT3 DNA damage inducible transcript 3 increases expression
multiple interactions
EXP Atazanavir Sulfate results in increased expression of DDIT3 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA
CTD PMID:32152650 NCBI chr12:57,516,588...57,520,517
Ensembl chr12:57,516,588...57,521,737
JBrowse link
G DNAJB9 DnaJ heat shock protein family (Hsp40) member B9 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of DNAJB9 mRNA CTD PMID:33819548 NCBI chr 7:108,569,874...108,574,850
Ensembl chr 7:108,569,867...108,574,850
JBrowse link
G DNAJC10 DnaJ heat shock protein family (Hsp40) member C10 increases expression
multiple interactions
EXP Atazanavir Sulfate results in increased expression of DNAJC10 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA
CTD PMID:32152650 NCBI chr 2:182,716,257...182,794,464
Ensembl chr 2:182,716,255...182,794,464
JBrowse link
G DNAJC12 DnaJ heat shock protein family (Hsp40) member C12 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of DNAJC12 mRNA CTD PMID:33819548 NCBI chr10:67,796,669...67,838,188
Ensembl chr10:67,796,669...67,838,188
JBrowse link
G DNAJC9 DnaJ heat shock protein family (Hsp40) member C9 increases expression EXP Atazanavir Sulfate results in increased expression of DNAJC9 mRNA CTD PMID:32152650 NCBI chr10:73,232,272...73,247,255
Ensembl chr10:73,183,362...73,247,255
JBrowse link
G EPHX1 epoxide hydrolase 1 multiple interactions
decreases expression
EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA
Atazanavir Sulfate results in decreased expression of EPHX1 mRNA
CTD PMID:32152650 NCBI chr 1:225,810,124...225,845,563
Ensembl chr 1:225,810,124...225,845,563
JBrowse link
G FKBP5 FKBP prolyl isomerase 5 multiple interactions
decreases expression
EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA
Atazanavir Sulfate results in decreased expression of FKBP5 mRNA
CTD PMID:32152650 NCBI chr 6:35,573,590...35,728,583
Ensembl chr 6:35,573,585...35,728,583
JBrowse link
G FMO1 flavin containing dimethylaniline monoxygenase 1 decreases expression EXP Atazanavir Sulfate results in decreased expression of FMO1 mRNA CTD PMID:32152650 NCBI chr 1:171,248,494...171,285,978
Ensembl chr 1:171,248,471...171,285,978
JBrowse link
G FOSL1 FOS like 1, AP-1 transcription factor subunit increases expression
multiple interactions
EXP Atazanavir Sulfate results in increased expression of FOSL1 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA
CTD PMID:32152650 NCBI chr11:65,892,049...65,900,545
Ensembl chr11:65,892,049...65,900,573
JBrowse link
G GGT1 gamma-glutamyltransferase 1 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of GGT1 mRNA CTD PMID:33819548 NCBI chr22:24,583,750...24,628,996
Ensembl chr22:24,594,811...24,629,005
JBrowse link
G GJB1 gap junction protein beta 1 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of GJB1 mRNA CTD PMID:33819548 NCBI chr  X:71,215,239...71,225,516
Ensembl chr  X:71,212,811...71,225,516
JBrowse link
G GK glycerol kinase multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of GK mRNA CTD PMID:33819548 NCBI chr  X:30,653,423...30,731,462
Ensembl chr  X:30,653,359...30,731,462
JBrowse link
G GPRC5B G protein-coupled receptor class C group 5 member B multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of GPRC5B mRNA CTD PMID:33819548 NCBI chr16:19,856,691...19,885,634
Ensembl chr16:19,856,691...19,886,167
JBrowse link
G GPX2 glutathione peroxidase 2 decreases expression
multiple interactions
EXP Atazanavir Sulfate results in decreased expression of GPX2 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of GPX2 mRNA
CTD PMID:32152650 PMID:33819548 NCBI chr14:64,939,158...64,942,745
Ensembl chr14:64,939,152...64,942,746
JBrowse link
G GSTA1 glutathione S-transferase alpha 1 multiple interactions
decreases expression
EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA
Atazanavir Sulfate results in decreased expression of GSTA1 mRNA
CTD PMID:32152650 NCBI chr 6:52,791,371...52,803,816
Ensembl chr 6:52,791,371...52,803,860
JBrowse link
G GSTA3 glutathione S-transferase alpha 3 decreases expression
multiple interactions
EXP Atazanavir Sulfate results in decreased expression of GSTA3 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA3 mRNA
CTD PMID:32152650 NCBI chr 6:52,896,646...52,909,698
Ensembl chr 6:52,896,639...52,909,698
JBrowse link
G GSTM4 glutathione S-transferase mu 4 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA CTD PMID:32152650 NCBI chr 1:109,656,099...109,667,727
Ensembl chr 1:109,656,099...109,665,496
JBrowse link
G HACL1 2-hydroxyacyl-CoA lyase 1 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of HACL1 mRNA CTD PMID:33819548 NCBI chr 3:15,560,699...15,601,569
Ensembl chr 3:15,560,699...15,601,852
JBrowse link
G HGF hepatocyte growth factor multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of HGF mRNA CTD PMID:33819548 NCBI chr 7:81,699,010...81,770,047
Ensembl chr 7:81,699,010...81,770,438
JBrowse link
G HMOX1 heme oxygenase 1 increases expression
multiple interactions
EXP Atazanavir Sulfate results in increased expression of HMOX1 mRNA; Atazanavir Sulfate results in increased expression of HMOX1 protein
Atazanavir Sulfate promotes the reaction [HMOX1 protein results in increased chemical synthesis of Bilirubin]; Ritonavir promotes the reaction [Atazanavir Sulfate results in increased expression of HMOX1 mRNA]
CTD PMID:26968795 NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214
JBrowse link
G HPX hemopexin multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of HPX mRNA CTD PMID:33819548 NCBI chr11:6,431,049...6,440,987
Ensembl chr11:6,431,049...6,442,617
JBrowse link
G HSPA5 heat shock protein family A (Hsp70) member 5 multiple interactions
decreases expression
EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA
Atazanavir Sulfate results in decreased expression of HSPA5 mRNA
CTD PMID:32152650 NCBI chr 9:125,234,853...125,241,343
Ensembl chr 9:125,234,853...125,241,382
JBrowse link
G ICAM1 intercellular adhesion molecule 1 increases expression EXP Atazanavir Sulfate results in increased expression of ICAM1 protein CTD PMID:26968795 NCBI chr19:10,271,120...10,286,615
Ensembl chr19:10,271,093...10,286,615
JBrowse link
G IER3 immediate early response 3 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of IER3 mRNA CTD PMID:33819548 NCBI chr 6:30,743,199...30,744,547
Ensembl chr 6:30,743,199...30,744,548
JBrowse link
G IFI16 interferon gamma inducible protein 16 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of IFI16 mRNA CTD PMID:33819548 NCBI chr 1:158,999,976...159,055,151
Ensembl chr 1:158,999,968...159,055,155
JBrowse link
G IFI27 interferon alpha inducible protein 27 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of IFI27 mRNA CTD PMID:33819548 NCBI chr14:94,105,894...94,116,690
Ensembl chr14:94,104,836...94,116,695
JBrowse link
G IGFBP1 insulin like growth factor binding protein 1 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of IGFBP1 mRNA CTD PMID:33819548 NCBI chr 7:45,888,488...45,893,660
Ensembl chr 7:45,888,360...45,893,660
JBrowse link
G IL6 interleukin 6 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of IL6 mRNA CTD PMID:33819548 NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002
JBrowse link
G JUN Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA CTD PMID:32152650 NCBI chr 1:58,780,791...58,784,047
Ensembl chr 1:58,776,845...58,784,048
JBrowse link
G JUND JunD proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA CTD PMID:32152650 NCBI chr19:18,279,694...18,281,622
Ensembl chr19:18,279,694...18,281,622
JBrowse link
G KYNU kynureninase multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of KYNU mRNA CTD PMID:33819548 NCBI chr 2:142,877,664...143,055,833
Ensembl chr 2:142,877,657...143,055,833
JBrowse link
G LBP lipopolysaccharide binding protein multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of LBP mRNA CTD PMID:33819548 NCBI chr20:38,346,482...38,377,013
Ensembl chr20:38,346,482...38,377,013
JBrowse link
G LDLR low density lipoprotein receptor multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of LDLR mRNA CTD PMID:33819548 NCBI chr19:11,089,463...11,133,820
Ensembl chr19:11,089,418...11,133,820
JBrowse link
G LIPC lipase C, hepatic type multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of LIPC mRNA CTD PMID:33819548 NCBI chr15:58,431,991...58,569,844
Ensembl chr15:58,410,569...58,569,844
JBrowse link
G LY96 lymphocyte antigen 96 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of LY96 mRNA CTD PMID:33819548 NCBI chr 8:73,991,392...74,099,857
Ensembl chr 8:73,991,392...74,029,079
JBrowse link
G MAFF MAF bZIP transcription factor F multiple interactions
increases expression
EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA
Atazanavir Sulfate results in increased expression of MAFF mRNA
CTD PMID:32152650 NCBI chr22:38,201,994...38,216,511
Ensembl chr22:38,200,767...38,216,507
JBrowse link
G MAP1LC3B microtubule associated protein 1 light chain 3 beta increases expression
multiple interactions
EXP Atazanavir Sulfate results in increased expression of MAP1LC3B mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA
CTD PMID:32152650 NCBI chr16:87,392,336...87,404,774
Ensembl chr16:87,383,953...87,404,779
JBrowse link
G MAP2K6 mitogen-activated protein kinase kinase 6 decreases expression
multiple interactions
EXP Atazanavir Sulfate results in decreased expression of MAP2K6 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA
CTD PMID:32152650 NCBI chr17:69,414,697...69,553,865
Ensembl chr17:69,414,697...69,553,865
JBrowse link
G MAPKAPK3 MAPK activated protein kinase 3 multiple interactions
increases expression
EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA
Atazanavir Sulfate results in increased expression of MAPKAPK3 mRNA
CTD PMID:32152650 NCBI chr 3:50,611,520...50,649,291
Ensembl chr 3:50,611,520...50,649,291
JBrowse link
G MLKL mixed lineage kinase domain like pseudokinase increases expression
multiple interactions
EXP Atazanavir Sulfate results in increased expression of MLKL mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of MLKL mRNA
CTD PMID:32152650 PMID:33819548 NCBI chr16:74,671,855...74,700,862
Ensembl chr16:74,671,855...74,700,960
JBrowse link
G MMUT methylmalonyl-CoA mutase multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of MMUT mRNA CTD PMID:33819548 NCBI chr 6:49,430,360...49,463,253
Ensembl chr 6:49,430,360...49,463,253
JBrowse link
G MTTP microsomal triglyceride transfer protein multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of MTTP mRNA CTD PMID:33819548 NCBI chr 4:99,564,130...99,623,997
Ensembl chr 4:99,564,081...99,623,997
JBrowse link
G NFXL1 nuclear transcription factor, X-box binding like 1 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of NFXL1 mRNA CTD PMID:33819548 NCBI chr 4:47,847,233...47,914,667
Ensembl chr 4:47,847,233...47,914,667
JBrowse link
G NR1H3 nuclear receptor subfamily 1 group H member 3 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of NR1H3 mRNA CTD PMID:33819548 NCBI chr11:47,248,300...47,269,033
Ensembl chr11:47,248,300...47,269,033
JBrowse link
G NR1H4 nuclear receptor subfamily 1 group H member 4 multiple interactions
decreases expression
EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA
Atazanavir Sulfate results in decreased expression of NR1H4 mRNA
CTD PMID:32152650 NCBI chr12:100,473,866...100,564,414
Ensembl chr12:100,473,708...100,564,414
JBrowse link
G NR1I2 nuclear receptor subfamily 1 group I member 2 decreases expression
multiple interactions
EXP Atazanavir Sulfate results in decreased expression of NR1I2 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I2 mRNA
CTD PMID:32152650 NCBI chr 3:119,782,101...119,818,487
Ensembl chr 3:119,780,484...119,818,487
JBrowse link
G NR1I3 nuclear receptor subfamily 1 group I member 3 decreases expression
multiple interactions
EXP Atazanavir Sulfate results in decreased expression of NR1I3 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA
CTD PMID:32152650 NCBI chr 1:161,229,669...161,238,203
Ensembl chr 1:161,229,666...161,238,244
JBrowse link
G PAH phenylalanine hydroxylase multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of PAH mRNA CTD PMID:33819548 NCBI chr12:102,836,889...102,958,441
Ensembl chr12:102,836,889...102,958,410
JBrowse link
G PIK3C2G phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 gamma decreases expression
multiple interactions
EXP Atazanavir Sulfate results in decreased expression of PIK3C2G mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA
CTD PMID:32152650 NCBI chr12:18,242,961...18,726,817
Ensembl chr12:18,242,961...18,648,416
JBrowse link
G PIK3R1 phosphoinositide-3-kinase regulatory subunit 1 multiple interactions
decreases expression
EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA
Atazanavir Sulfate results in decreased expression of PIK3R1 mRNA
CTD PMID:32152650 NCBI chr 5:68,215,756...68,301,821
Ensembl chr 5:68,215,740...68,301,821
JBrowse link
G PON1 paraoxonase 1 decreases activity ISO Atazanavir Sulfate results in decreased activity of PON1 protein CTD PMID:27378623 NCBI chr 7:95,297,676...95,324,532
Ensembl chr 7:95,297,676...95,324,532
JBrowse link
G PPARA peroxisome proliferator activated receptor alpha multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of PPARA mRNA CTD PMID:33819548 NCBI chr22:46,150,526...46,243,756
Ensembl chr22:46,150,521...46,243,755
JBrowse link
G PPP1R3C protein phosphatase 1 regulatory subunit 3C multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of PPP1R3C mRNA CTD PMID:33819548 NCBI chr10:91,628,442...91,633,071
Ensembl chr10:91,628,442...91,633,071
JBrowse link
G RALA RAS like proto-oncogene A multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA CTD PMID:32152650 NCBI chr 7:39,623,572...39,708,120
Ensembl chr 7:39,623,565...39,708,120
JBrowse link
G REEP5 receptor accessory protein 5 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of REEP5 mRNA CTD PMID:33819548 NCBI chr 5:112,876,385...112,922,227
Ensembl chr 5:112,876,385...112,922,289
JBrowse link
G RIPK1 receptor interacting serine/threonine kinase 1 multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA CTD PMID:32152650 NCBI chr 6:3,063,967...3,115,187
Ensembl chr 6:3,063,824...3,115,187
JBrowse link
G SCP2 sterol carrier protein 2 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SCP2 mRNA CTD PMID:33819548 NCBI chr 1:52,927,276...53,051,698
Ensembl chr 1:52,927,276...53,051,698
JBrowse link
G SDC2 syndecan 2 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SDC2 mRNA CTD PMID:33819548 NCBI chr 8:96,493,813...96,611,790
Ensembl chr 8:96,493,813...96,611,790
JBrowse link
G SERPINE1 serpin family E member 1 increases expression
multiple interactions
EXP Atazanavir Sulfate results in increased expression of SERPINE1 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA
CTD PMID:32152650 NCBI chr 7:101,127,104...101,139,247
Ensembl chr 7:101,127,104...101,139,247
JBrowse link
G SH3GLB1 SH3 domain containing GRB2 like, endophilin B1 multiple interactions
increases expression
EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA
Atazanavir Sulfate results in increased expression of SH3GLB1 mRNA
CTD PMID:32152650 NCBI chr 1:86,704,576...86,748,184
Ensembl chr 1:86,704,570...86,748,184
JBrowse link
G SLC10A1 solute carrier family 10 member 1 decreases expression
multiple interactions
EXP Atazanavir Sulfate results in decreased expression of SLC10A1 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA
CTD PMID:32152650 NCBI chr14:69,775,416...69,797,241
Ensembl chr14:69,775,416...69,797,241
JBrowse link
G SLC17A1 solute carrier family 17 member 1 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SLC17A1 mRNA CTD PMID:33819548 NCBI chr 6:25,723,743...25,832,052
Ensembl chr 6:25,782,915...25,832,052
JBrowse link
G SLC22A1 solute carrier family 22 member 1 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SLC22A1 mRNA CTD PMID:33819548 NCBI chr 6:160,121,815...160,158,718
Ensembl chr 6:160,121,815...160,158,718
JBrowse link
G SLC51A solute carrier family 51 member A multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA CTD PMID:32152650 NCBI chr 3:196,216,534...196,233,427
Ensembl chr 3:196,211,487...196,243,178
JBrowse link
G SLC51B SLC51 subunit beta multiple interactions EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA CTD PMID:32152650 NCBI chr15:65,045,387...65,053,397
Ensembl chr15:65,045,387...65,053,397
JBrowse link
G SLCO1B1 solute carrier organic anion transporter family member 1B1 decreases expression
multiple interactions
EXP Atazanavir Sulfate results in decreased expression of SLCO1B1 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLCO1B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SLCO1B1 mRNA
CTD PMID:32152650 PMID:33819548 NCBI chr12:21,131,194...21,239,796
Ensembl chr12:21,131,194...21,239,796
JBrowse link
G SOD2 superoxide dismutase 2 multiple interactions
increases expression
EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA
Atazanavir Sulfate results in increased expression of SOD2 mRNA
CTD PMID:32152650 NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529
JBrowse link
G SORL1 sortilin related receptor 1 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SORL1 mRNA CTD PMID:33819548 NCBI chr11:121,452,314...121,633,763
Ensembl chr11:121,452,314...121,633,763
JBrowse link
G SQSTM1 sequestosome 1 multiple interactions
increases expression
EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA
Atazanavir Sulfate results in increased expression of SQSTM1 mRNA
CTD PMID:32152650 NCBI chr 5:179,806,393...179,838,078
Ensembl chr 5:179,806,398...179,838,078
JBrowse link
G SREBF1 sterol regulatory element binding transcription factor 1 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SREBF1 mRNA CTD PMID:33819548 NCBI chr17:17,811,334...17,836,986
Ensembl chr17:17,810,399...17,837,002
JBrowse link
G SRP72 signal recognition particle 72 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of SRP72 mRNA CTD PMID:33819548 NCBI chr 4:56,467,617...56,503,681
Ensembl chr 4:56,467,617...56,503,681
JBrowse link
G SULT2A1 sulfotransferase family 2A member 1 multiple interactions
decreases expression
EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA
Atazanavir Sulfate results in decreased expression of SULT2A1 mRNA
CTD PMID:32152650 NCBI chr19:47,870,467...47,886,315
Ensembl chr19:47,870,467...47,886,315
JBrowse link
G TFPI tissue factor pathway inhibitor multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TFPI mRNA CTD PMID:33819548 NCBI chr 2:187,464,230...187,554,435
Ensembl chr 2:187,464,230...187,565,760
JBrowse link
G TLR4 toll like receptor 4 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TLR4 mRNA CTD PMID:33819548 NCBI chr 9:117,704,403...117,724,735
Ensembl chr 9:117,704,175...117,724,735
JBrowse link
G TNFRSF10A TNF receptor superfamily member 10a multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TNFRSF10A mRNA CTD PMID:33819548 NCBI chr 8:23,190,452...23,225,102
Ensembl chr 8:23,190,452...23,225,102
JBrowse link
G TNFSF10 TNF superfamily member 10 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of TNFSF10 mRNA CTD PMID:33819548 NCBI chr 3:172,505,508...172,523,430
Ensembl chr 3:172,505,508...172,523,475
JBrowse link
G TNFSF11 TNF superfamily member 11 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TNFSF11 mRNA CTD PMID:33819548 NCBI chr13:42,562,736...42,608,013
Ensembl chr13:42,562,736...42,608,013
JBrowse link
G UGT2B15 UDP glucuronosyltransferase family 2 member B15 multiple interactions EXP [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of UGT2B15 mRNA CTD PMID:33819548 NCBI chr 4:68,646,597...68,670,652
Ensembl chr 4:68,646,597...68,670,652
JBrowse link
G UGT2B4 UDP glucuronosyltransferase family 2 member B4 multiple interactions
decreases expression
EXP [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of UGT2B4 mRNA
Atazanavir Sulfate results in decreased expression of UGT2B4 mRNA
CTD PMID:32152650 NCBI chr 4:69,480,165...69,526,014
Ensembl chr 4:69,480,165...69,526,014
JBrowse link
cefoselis sulfate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G SLC22A6 solute carrier family 22 member 6 multiple interactions EXP cefoselis inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid] CTD PMID:16098483 NCBI chr11:62,976,597...62,984,967
Ensembl chr11:62,936,385...62,984,967
JBrowse link
G SLC22A8 solute carrier family 22 member 8 increases uptake
multiple interactions
EXP SLC22A8 protein results in increased uptake of cefoselis
cefoselis inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]
CTD PMID:16098483 NCBI chr11:62,992,824...63,015,841
Ensembl chr11:62,989,154...63,015,841
JBrowse link
erythromycin estolate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABCB1 ATP binding cassette subfamily B member 1 increases expression ISO Erythromycin Estolate results in increased expression of ABCB1 mRNA; Erythromycin Estolate results in increased expression of ABCB1A mRNA CTD PMID:17522070 PMID:24412560 NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323
JBrowse link
G ABCB11 ATP binding cassette subfamily B member 11 decreases expression
decreases activity
ISO
EXP
Erythromycin Estolate results in decreased expression of ABCB11 mRNA
Erythromycin Estolate results in decreased activity of ABCB11 protein
CTD PMID:17522070 PMID:20829430 PMID:23956101 PMID:28437613 NCBI chr 2:168,915,390...169,031,324
Ensembl chr 2:168,915,498...169,031,324
JBrowse link
G ABCC3 ATP binding cassette subfamily C member 3 increases expression ISO Erythromycin Estolate results in increased expression of ABCC3 mRNA CTD PMID:17522070 PMID:24412560 NCBI chr17:50,634,881...50,692,253
Ensembl chr17:50,634,777...50,692,253
JBrowse link
G ABCG5 ATP binding cassette subfamily G member 5 increases expression ISO Erythromycin Estolate results in increased expression of ABCG5 mRNA CTD PMID:24412560 NCBI chr 2:43,806,211...43,839,231
Ensembl chr 2:43,812,472...43,838,865
JBrowse link
G ABCG8 ATP binding cassette subfamily G member 8 increases expression ISO Erythromycin Estolate results in increased expression of ABCG8 mRNA CTD PMID:24412560 NCBI chr 2:43,838,971...43,882,988
Ensembl chr 2:43,831,942...43,882,988
JBrowse link
G ACADM acyl-CoA dehydrogenase medium chain decreases expression ISO Erythromycin Estolate results in decreased expression of ACADM mRNA CTD PMID:17522070 NCBI chr 1:75,724,709...75,763,679
Ensembl chr 1:75,724,431...75,787,575
JBrowse link
G ACLY ATP citrate lyase decreases expression ISO Erythromycin Estolate results in decreased expression of ACLY mRNA CTD PMID:17522070 NCBI chr17:41,866,917...41,930,545
Ensembl chr17:41,866,917...41,930,542
JBrowse link
G ACSL1 acyl-CoA synthetase long chain family member 1 decreases expression ISO Erythromycin Estolate results in decreased expression of ACSL1 mRNA CTD PMID:17522070 NCBI chr 4:184,755,595...184,826,594
Ensembl chr 4:184,755,595...184,826,818
JBrowse link
G ALDH1A1 aldehyde dehydrogenase 1 family member A1 increases expression ISO Erythromycin Estolate results in increased expression of ALDH1A1 mRNA CTD PMID:24412560 NCBI chr 9:72,900,671...72,953,053
Ensembl chr 9:72,900,671...73,080,442
JBrowse link
G ALDH3A2 aldehyde dehydrogenase 3 family member A2 decreases expression ISO Erythromycin Estolate results in decreased expression of ALDH3A2 mRNA CTD PMID:17522070 NCBI chr17:19,648,136...19,677,596
Ensembl chr17:19,648,136...19,685,760
JBrowse link
G APEX1 apurinic/apyrimidinic endodeoxyribonuclease 1 decreases expression ISO Erythromycin Estolate results in decreased expression of APEX1 mRNA CTD PMID:17522070 NCBI chr14:20,455,226...20,457,767
Ensembl chr14:20,455,191...20,457,772
JBrowse link
G ASPM assembly factor for spindle microtubules decreases expression
increases expression
ISO Erythromycin Estolate results in decreased expression of ASPM mRNA
Erythromycin Estolate results in increased expression of ASPM mRNA
CTD PMID:24412560 NCBI chr 1:197,084,127...197,146,669
Ensembl chr 1:197,084,121...197,146,694
JBrowse link
G AURKB aurora kinase B increases expression
decreases expression
ISO Erythromycin Estolate results in increased expression of AURKB mRNA
Erythromycin Estolate results in decreased expression of AURKB mRNA
CTD PMID:24412560 NCBI chr17:8,204,731...8,210,575
Ensembl chr17:8,204,733...8,210,600
JBrowse link
G BAX BCL2 associated X, apoptosis regulator decreases expression ISO Erythromycin Estolate results in decreased expression of BAX mRNA CTD PMID:12883083 NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798
JBrowse link
G BCL2 BCL2 apoptosis regulator increases expression ISO Erythromycin Estolate results in increased expression of BCL2 mRNA CTD PMID:12883083 NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128
JBrowse link
G BTG2 BTG anti-proliferation factor 2 increases expression ISO Erythromycin Estolate results in increased expression of BTG2 mRNA CTD PMID:17522070 NCBI chr 1:203,305,519...203,309,602
Ensembl chr 1:203,305,491...203,309,602
JBrowse link
G CA1 carbonic anhydrase 1 decreases expression ISO Erythromycin Estolate results in decreased expression of CAR1 mRNA CTD PMID:24412560 NCBI chr 8:85,327,608...85,378,113
Ensembl chr 8:85,327,608...85,379,014
JBrowse link
G CACNA1I calcium voltage-gated channel subunit alpha1 I decreases expression ISO Erythromycin Estolate results in decreased expression of CACNA1I mRNA CTD PMID:24412560 NCBI chr22:39,570,753...39,689,735
Ensembl chr22:39,570,753...39,689,735
JBrowse link
G CALU calumenin increases expression ISO Erythromycin Estolate results in increased expression of CALU mRNA CTD PMID:17522070 NCBI chr 7:128,739,359...128,773,400
Ensembl chr 7:128,739,292...128,773,400
JBrowse link
G CAT catalase decreases expression ISO Erythromycin Estolate results in decreased expression of CAT mRNA CTD PMID:17522070 NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
JBrowse link
G CCN2 cellular communication network factor 2 decreases expression ISO Erythromycin Estolate results in decreased expression of CCN2 mRNA CTD PMID:24412560 NCBI chr 6:131,948,176...131,951,372
Ensembl chr 6:131,948,176...131,951,372
JBrowse link
G CCNA2 cyclin A2 increases expression
decreases expression
ISO Erythromycin Estolate results in increased expression of CCNA2 mRNA
Erythromycin Estolate results in decreased expression of CCNA2 mRNA
CTD PMID:24412560 NCBI chr 4:121,816,444...121,823,883
Ensembl chr 4:121,816,444...121,823,883
JBrowse link
G CCNB1 cyclin B1 decreases expression
increases expression
ISO Erythromycin Estolate results in decreased expression of CCNB1 mRNA
Erythromycin Estolate results in increased expression of CCNB1 mRNA
CTD PMID:24412560 NCBI chr 5:69,167,150...69,178,245
Ensembl chr 5:69,167,135...69,178,245
JBrowse link
G CDCA3 cell division cycle associated 3 decreases expression
increases expression
ISO Erythromycin Estolate results in decreased expression of CDCA3 mRNA
Erythromycin Estolate results in increased expression of CDCA3 mRNA
CTD PMID:24412560 NCBI chr12:6,844,798...6,851,286
Ensembl chr12:6,844,793...6,851,292
JBrowse link
G CDK1 cyclin dependent kinase 1 increases expression
decreases expression
ISO Erythromycin Estolate results in increased expression of CDK1 mRNA
Erythromycin Estolate results in decreased expression of CDK1 mRNA
CTD PMID:24412560 NCBI chr10:60,778,331...60,794,852
Ensembl chr10:60,778,331...60,794,852
JBrowse link
G CEACAM1 CEA cell adhesion molecule 1 decreases expression ISO Erythromycin Estolate results in decreased expression of CEACAM1 mRNA CTD PMID:17522070 NCBI chr19:42,507,306...42,528,481
Ensembl chr19:42,507,304...42,561,234
JBrowse link
G CENPW centromere protein W increases expression
decreases expression
ISO Erythromycin Estolate results in increased expression of CENPW mRNA
Erythromycin Estolate results in decreased expression of CENPW mRNA
CTD PMID:24412560 NCBI chr 6:126,340,115...126,483,320
Ensembl chr 6:126,340,115...126,348,875
JBrowse link
G CES2 carboxylesterase 2 increases expression ISO Erythromycin Estolate results in increased expression of CES2 mRNA CTD PMID:24412560 NCBI chr16:66,934,471...66,945,096
Ensembl chr16:66,934,444...66,945,096
JBrowse link
G CHD2 chromodomain helicase DNA binding protein 2 increases expression ISO Erythromycin Estolate results in increased expression of CHD2 mRNA CTD PMID:24412560 NCBI chr15:92,900,324...93,027,996
Ensembl chr15:92,886,203...93,027,996
JBrowse link
G CTSL cathepsin L increases expression ISO Erythromycin Estolate results in increased expression of CTSL mRNA CTD PMID:17522070 NCBI chr 9:87,726,119...87,731,469
Ensembl chr 9:87,724,051...87,731,469
JBrowse link
G CYB5R3 cytochrome b5 reductase 3 decreases expression ISO Erythromycin Estolate results in decreased expression of CYB5R3 mRNA CTD PMID:17522070 NCBI chr22:42,617,840...42,649,392
Ensembl chr22:42,615,730...42,720,870
JBrowse link
G CYP1A1 cytochrome P450 family 1 subfamily A member 1 increases expression ISO Erythromycin Estolate results in increased expression of CYP1A1 mRNA CTD PMID:24412560 NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536
JBrowse link
G CYP3A5 cytochrome P450 family 3 subfamily A member 5 increases expression ISO Erythromycin Estolate results in increased expression of CYP3A9 mRNA CTD PMID:24412560 NCBI chr 7:99,648,194...99,679,996
Ensembl chr 7:99,648,194...99,679,996
JBrowse link
G CYP8B1 cytochrome P450 family 8 subfamily B member 1 increases expression ISO Erythromycin Estolate results in increased expression of CYP8B1 mRNA CTD PMID:24412560 NCBI chr 3:42,872,192...42,875,879
Ensembl chr 3:42,856,005...42,875,898
JBrowse link
G DDIT3 DNA damage inducible transcript 3 increases expression ISO Erythromycin Estolate results in increased expression of DDIT3 mRNA CTD PMID:17522070 NCBI chr12:57,516,588...57,520,517
Ensembl chr12:57,516,588...57,521,737
JBrowse link
G DUT deoxyuridine triphosphatase increases expression ISO Erythromycin Estolate results in increased expression of DUT mRNA CTD PMID:24412560 NCBI chr15:48,331,095...48,343,373
Ensembl chr15:48,331,011...48,343,373
JBrowse link
G ECT2 epithelial cell transforming 2 decreases expression
increases expression
ISO Erythromycin Estolate results in decreased expression of ECT2 mRNA
Erythromycin Estolate results in increased expression of ECT2 mRNA
CTD PMID:24412560 NCBI chr 3:172,750,726...172,829,265
Ensembl chr 3:172,750,682...172,821,474
JBrowse link
G FABP1 fatty acid binding protein 1 increases expression ISO Erythromycin Estolate results in increased expression of FABP1 mRNA CTD PMID:17522070 NCBI chr 2:88,122,982...88,128,062
Ensembl chr 2:88,122,982...88,128,062
JBrowse link
G FADS1 fatty acid desaturase 1 decreases expression ISO Erythromycin Estolate results in decreased expression of FADS1 mRNA CTD PMID:17522070 NCBI chr11:61,799,627...61,817,003
Ensembl chr11:61,799,627...61,829,318
JBrowse link
G FAM111A FAM111 trypsin like peptidase A increases expression
decreases expression
ISO Erythromycin Estolate results in increased expression of FAM111A mRNA
Erythromycin Estolate results in decreased expression of FAM111A mRNA
CTD PMID:24412560 NCBI chr11:59,142,856...59,155,039
Ensembl chr11:59,142,748...59,155,039
JBrowse link
G FASN fatty acid synthase decreases expression ISO Erythromycin Estolate results in decreased expression of FASN mRNA CTD PMID:17522070 NCBI chr17:82,078,338...82,098,236
Ensembl chr17:82,078,338...82,098,294
JBrowse link
G FGA fibrinogen alpha chain increases expression ISO Erythromycin Estolate results in increased expression of FGA mRNA CTD PMID:17522070 NCBI chr 4:154,583,126...154,590,742
Ensembl chr 4:154,583,126...154,590,742
JBrowse link
G FGB fibrinogen beta chain increases expression ISO Erythromycin Estolate results in increased expression of FGB mRNA CTD PMID:17522070 NCBI chr 4:154,562,980...154,572,807
Ensembl chr 4:154,563,011...154,572,807
JBrowse link
G FMO1 flavin containing dimethylaniline monoxygenase 1 decreases expression ISO Erythromycin Estolate results in decreased expression of FMO1 mRNA CTD PMID:17522070 NCBI chr 1:171,248,494...171,285,978
Ensembl chr 1:171,248,471...171,285,978
JBrowse link
G G6PC1 glucose-6-phosphatase catalytic subunit 1 decreases expression ISO Erythromycin Estolate results in decreased expression of G6PC1 mRNA CTD PMID:24412560 NCBI chr17:42,900,799...42,914,438
Ensembl chr17:42,900,797...42,914,438
JBrowse link
G GADD45A growth arrest and DNA damage inducible alpha increases expression ISO Erythromycin Estolate results in increased expression of GADD45A mRNA CTD PMID:17522070 NCBI chr 1:67,685,201...67,688,334
Ensembl chr 1:67,685,201...67,688,334
JBrowse link
G GCK glucokinase decreases expression ISO Erythromycin Estolate results in decreased expression of GCK mRNA CTD PMID:17522070 NCBI chr 7:44,143,213...44,189,439
Ensembl chr 7:44,143,213...44,198,170
JBrowse link
G GPX1 glutathione peroxidase 1 decreases expression ISO Erythromycin Estolate results in decreased expression of GPX1 mRNA CTD PMID:17522070 NCBI chr 3:49,357,176...49,358,353
Ensembl chr 3:49,357,174...49,358,605
JBrowse link
G GPX2 glutathione peroxidase 2 increases expression ISO Erythromycin Estolate results in increased expression of GPX2 mRNA CTD PMID:24412560 NCBI chr14:64,939,158...64,942,745
Ensembl chr14:64,939,152...64,942,746
JBrowse link
G GSTM3 glutathione S-transferase mu 3 decreases expression ISO Erythromycin Estolate results in decreased expression of GSTM3 mRNA CTD PMID:17522070 NCBI chr 1:109,733,937...109,741,038
Ensembl chr 1:109,733,932...109,741,038
JBrowse link
G HIBADH 3-hydroxyisobutyrate dehydrogenase decreases expression ISO Erythromycin Estolate results in decreased expression of HIBADH mRNA CTD PMID:17522070 NCBI chr 7:27,525,442...27,662,883
Ensembl chr 7:27,525,442...27,662,883
JBrowse link
G HMMR hyaluronan mediated motility receptor increases expression
decreases expression
ISO Erythromycin Estolate results in increased expression of HMMR mRNA
Erythromycin Estolate results in decreased expression of HMMR mRNA
CTD PMID:24412560 NCBI chr 5:163,460,632...163,491,941
Ensembl chr 5:163,460,203...163,491,941
JBrowse link
G IGF2R insulin like growth factor 2 receptor increases expression ISO Erythromycin Estolate results in increased expression of IGF2R mRNA CTD PMID:24412560 NCBI chr 6:159,969,082...160,111,504
Ensembl chr 6:159,969,082...160,113,507
JBrowse link
G IGFBP1 insulin like growth factor binding protein 1 increases expression ISO Erythromycin Estolate results in increased expression of IGFBP1 mRNA CTD PMID:17522070 NCBI chr 7:45,888,488...45,893,660
Ensembl chr 7:45,888,360...45,893,660
JBrowse link
G IGFBP2 insulin like growth factor binding protein 2 increases expression ISO Erythromycin Estolate results in increased expression of IGFBP2 mRNA CTD PMID:24412560 NCBI chr 2:216,632,828...216,664,436
Ensembl chr 2:216,632,828...216,664,436
JBrowse link
G IP6K2 inositol hexakisphosphate kinase 2 decreases expression ISO Erythromycin Estolate results in decreased expression of IP6K2 mRNA CTD PMID:24412560 NCBI chr 3:48,688,003...48,717,221
Ensembl chr 3:48,688,003...48,740,353
JBrowse link
G ISY1 ISY1 splicing factor homolog increases expression ISO Erythromycin Estolate results in increased expression of ISY1 mRNA CTD PMID:24412560 NCBI chr 3:129,127,415...129,161,063
Ensembl chr 3:129,127,415...129,161,063
JBrowse link
G KIF20B kinesin family member 20B increases expression
decreases expression
ISO Erythromycin Estolate results in increased expression of KIF20B mRNA
Erythromycin Estolate results in decreased expression of KIF20B mRNA
CTD PMID:24412560 NCBI chr10:89,701,590...89,774,934
Ensembl chr10:89,701,590...89,774,939
JBrowse link
G KIF23 kinesin family member 23 increases expression
decreases expression
ISO Erythromycin Estolate results in increased expression of KIF23 mRNA
Erythromycin Estolate results in decreased expression of KIF23 mRNA
CTD PMID:24412560 NCBI chr15:69,414,349...69,448,427
Ensembl chr15:69,414,246...69,448,427
JBrowse link
G KIF2C kinesin family member 2C decreases expression
increases expression
ISO Erythromycin Estolate results in decreased expression of KIF2C mRNA
Erythromycin Estolate results in increased expression of KIF2C mRNA
CTD PMID:24412560 NCBI chr 1:44,739,837...44,767,767
Ensembl chr 1:44,739,818...44,767,767
JBrowse link
G KRT18 keratin 18 increases expression ISO Erythromycin Estolate results in increased expression of KRT18 mRNA CTD PMID:17522070 NCBI chr12:52,948,855...52,952,906
Ensembl chr12:52,948,871...52,952,906
JBrowse link
G LBP lipopolysaccharide binding protein increases expression ISO Erythromycin Estolate results in increased expression of LBP mRNA CTD PMID:17522070 NCBI chr20:38,346,482...38,377,013
Ensembl chr20:38,346,482...38,377,013
JBrowse link
G LGALS3 galectin 3 increases expression ISO Erythromycin Estolate results in increased expression of LGALS3 mRNA CTD PMID:17522070 NCBI chr14:55,129,252...55,145,430
Ensembl chr14:55,124,110...55,145,423
JBrowse link
G LIPC lipase C, hepatic type decreases expression ISO Erythromycin Estolate results in decreased expression of LIPC mRNA CTD PMID:17522070 NCBI chr15:58,431,991...58,569,844
Ensembl chr15:58,410,569...58,569,844
JBrowse link
G LPIN1 lipin 1 decreases expression ISO Erythromycin Estolate results in decreased expression of LPIN1 mRNA CTD PMID:24412560 NCBI chr 2:11,677,544...11,827,409
Ensembl chr 2:11,677,595...11,827,409
JBrowse link
G LPL lipoprotein lipase increases expression ISO Erythromycin Estolate results in increased expression of LPL mRNA CTD PMID:17522070 NCBI chr 8:19,939,253...19,967,259
Ensembl chr 8:19,901,717...19,967,259
JBrowse link
G MAOB monoamine oxidase B decreases expression ISO Erythromycin Estolate results in decreased expression of MAOB mRNA CTD PMID:17522070 NCBI chr  X:43,766,610...43,882,450
Ensembl chr  X:43,766,610...43,882,450
JBrowse link
G MIR16-2 microRNA 16-2 increases expression ISO Erythromycin Estolate results in increased expression of MIR16 mRNA CTD PMID:17522070 NCBI chr 3:160,404,745...160,404,825
Ensembl chr 3:160,404,745...160,404,825
JBrowse link
G MYC MYC proto-oncogene, bHLH transcription factor increases expression
decreases expression
ISO Erythromycin Estolate results in increased expression of MYC mRNA
Erythromycin Estolate results in decreased expression of MYC mRNA
CTD PMID:17522070 PMID:24412560 NCBI chr 8:127,735,434...127,742,951
Ensembl chr 8:127,735,434...127,742,951
JBrowse link
G NCAPH non-SMC condensin I complex subunit H decreases expression
increases expression
ISO Erythromycin Estolate results in decreased expression of NCAPH mRNA
Erythromycin Estolate results in increased expression of NCAPH mRNA
CTD PMID:24412560 NCBI chr 2:96,335,766...96,377,091
Ensembl chr 2:96,335,766...96,377,091
JBrowse link
G NFKBIB NFKB inhibitor beta decreases expression ISO Erythromycin Estolate results in decreased expression of NFKBIB mRNA CTD PMID:17522070 NCBI chr19:38,899,666...38,908,889
Ensembl chr19:38,899,700...38,908,893
JBrowse link
G NOCT nocturnin decreases expression ISO Erythromycin Estolate results in decreased expression of NOCT mRNA CTD PMID:24412560 NCBI chr 4:139,015,781...139,045,939
Ensembl chr 4:139,015,781...139,045,939
JBrowse link
G NUSAP1 nucleolar and spindle associated protein 1 increases expression
decreases expression
ISO Erythromycin Estolate results in increased expression of NUSAP1 mRNA
Erythromycin Estolate results in decreased expression of NUSAP1 mRNA
CTD PMID:24412560 NCBI chr15:41,332,881...41,381,046
Ensembl chr15:41,320,794...41,381,050
JBrowse link
G OTC ornithine transcarbamylase decreases expression ISO Erythromycin Estolate results in decreased expression of OTC mRNA CTD PMID:17522070 NCBI chr  X:38,327,684...38,422,928
Ensembl chr  X:38,327,598...38,422,908
JBrowse link
G PCLAF PCNA clamp associated factor decreases expression
increases expression
ISO Erythromycin Estolate results in decreased expression of PCLAF mRNA
Erythromycin Estolate results in increased expression of PCLAF mRNA
CTD PMID:24412560 NCBI chr15:64,364,304...64,387,687
Ensembl chr15:64,364,304...64,387,687
JBrowse link
G PCMTD1 protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1 decreases expression ISO Erythromycin Estolate results in decreased expression of PCMTD1 mRNA CTD PMID:24412560 NCBI chr 8:51,817,575...51,899,186
Ensembl chr 8:51,817,575...51,899,186
JBrowse link
G PDK4 pyruvate dehydrogenase kinase 4 decreases expression ISO Erythromycin Estolate results in decreased expression of PDK4 mRNA CTD PMID:24412560 NCBI chr 7:95,583,499...95,596,516
Ensembl chr 7:95,583,499...95,596,516
JBrowse link
G PER1 period circadian regulator 1 decreases expression ISO Erythromycin Estolate results in decreased expression of PER1 mRNA CTD PMID:24412560 NCBI chr17:8,140,472...8,152,404
Ensembl chr17:8,140,467...8,156,506
JBrowse link
G PFKFB3 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 decreases expression ISO Erythromycin Estolate results in decreased expression of PFKFB3 mRNA CTD PMID:24412560 NCBI chr10:6,144,921...6,326,637
Ensembl chr10:6,144,934...6,254,644
JBrowse link
G PKLR pyruvate kinase L/R decreases expression ISO Erythromycin Estolate results in decreased expression of PKLR mRNA CTD PMID:17522070 NCBI chr 1:155,289,293...155,308,654
Ensembl chr 1:155,289,293...155,301,438
JBrowse link
G PYGL glycogen phosphorylase L decreases expression ISO Erythromycin Estolate results in decreased expression of PYGL mRNA CTD PMID:17522070 NCBI chr14:50,905,217...50,944,483
Ensembl chr14:50,857,891...50,944,483
JBrowse link
G RAD51 RAD51 recombinase increases expression
decreases expression
ISO Erythromycin Estolate results in increased expression of RAD51 mRNA
Erythromycin Estolate results in decreased expression of RAD51 mRNA
CTD PMID:24412560 NCBI chr15:40,694,733...40,732,340
Ensembl chr15:40,694,774...40,732,340
JBrowse link
G RRM2 ribonucleotide reductase regulatory subunit M2 decreases expression
increases expression
ISO Erythromycin Estolate results in decreased expression of RRM2 mRNA
Erythromycin Estolate results in increased expression of RRM2 mRNA
CTD PMID:24412560 NCBI chr 2:10,122,568...10,211,010
Ensembl chr 2:10,120,698...10,211,725
JBrowse link
G S100A8 S100 calcium binding protein A8 increases expression ISO Erythromycin Estolate results in increased expression of S100A8 mRNA CTD PMID:17522070 NCBI chr 1:153,390,032...153,422,583
Ensembl chr 1:153,390,032...153,391,073
JBrowse link
G S100A9 S100 calcium binding protein A9 increases expression ISO Erythromycin Estolate results in increased expression of S100A9 mRNA CTD PMID:17522070 NCBI chr 1:153,357,854...153,361,023
Ensembl chr 1:153,357,854...153,361,023
JBrowse link
G SERPINA7 serpin family A member 7 increases expression ISO Erythromycin Estolate results in increased expression of SERPINA7 mRNA CTD PMID:24412560 NCBI chr  X:106,032,435...106,038,727
Ensembl chr  X:106,032,435...106,038,727
JBrowse link
G SERTAD3 SERTA domain containing 3 increases expression ISO Erythromycin Estolate results in increased expression of SERTAD3 mRNA CTD PMID:24412560 NCBI chr19:40,440,844...40,444,335
Ensembl chr19:40,440,844...40,444,335
JBrowse link
G SHCBP1 SHC binding and spindle associated 1 decreases expression
increases expression
ISO Erythromycin Estolate results in decreased expression of SHCBP1 mRNA
Erythromycin Estolate results in increased expression of SHCBP1 mRNA
CTD PMID:24412560 NCBI chr16:46,578,591...46,621,379
Ensembl chr16:46,578,591...46,621,379
JBrowse link
G SLC38A2 solute carrier family 38 member 2 decreases expression ISO Erythromycin Estolate results in decreased expression of SLC38A2 mRNA CTD PMID:24412560 NCBI chr12:46,358,188...46,372,773
Ensembl chr12:46,358,188...46,372,773
JBrowse link
G SLCO1A2 solute carrier organic anion transporter family member 1A2 increases expression ISO Erythromycin Estolate results in increased expression of SLCO1A4 mRNA CTD PMID:24412560 NCBI chr12:21,264,600...21,419,634
Ensembl chr12:21,264,600...21,419,594
JBrowse link
G SLCO1B3 solute carrier organic anion transporter family member 1B3 decreases expression ISO Erythromycin Estolate results in decreased expression of SLCO1B2 mRNA CTD PMID:17522070 NCBI chr12:20,810,705...20,916,911
Ensembl chr12:20,810,702...20,916,911
JBrowse link
G SPC25 SPC25 component of NDC80 kinetochore complex increases expression
decreases expression
ISO Erythromycin Estolate results in increased expression of SPC25 mRNA
Erythromycin Estolate results in decreased expression of SPC25 mRNA
CTD PMID:24412560 NCBI chr 2:168,861,521...168,890,430
Ensembl chr 2:168,834,132...168,913,371
JBrowse link
G SPIN2B spindlin family member 2B decreases expression ISO Erythromycin Estolate results in decreased expression of SPIN2B mRNA CTD PMID:17522070 NCBI chr  X:57,119,682...57,121,548
Ensembl chr  X:57,118,551...57,121,548
JBrowse link
G SPINK1 serine peptidase inhibitor Kazal type 1 increases expression ISO Erythromycin Estolate results in increased expression of SPINK1 mRNA CTD PMID:24412560 NCBI chr 5:147,824,582...147,839,196
Ensembl chr 5:147,824,572...147,831,671
JBrowse link
G SREBF1 sterol regulatory element binding transcription factor 1 decreases expression ISO Erythromycin Estolate results in decreased expression of SREBF1 mRNA CTD PMID:17522070 NCBI chr17:17,811,334...17,836,986
Ensembl chr17:17,810,399...17,837,002
JBrowse link
G STAT3 signal transducer and activator of transcription 3 increases expression ISO Erythromycin Estolate results in increased expression of STAT3 mRNA CTD PMID:17522070 NCBI chr17:42,313,324...42,388,442
Ensembl chr17:42,313,324...42,388,568
JBrowse link
G STYXL1 serine/threonine/tyrosine interacting like 1 increases expression ISO Erythromycin Estolate results in increased expression of STYXL1 mRNA CTD PMID:24412560 NCBI chr 7:75,996,337...76,048,000
Ensembl chr 7:75,996,338...76,048,004
JBrowse link
G SUGT1 SGT1 homolog, MIS12 kinetochore complex assembly cochaperone increases expression ISO Erythromycin Estolate results in increased expression of SUGT1 mRNA CTD PMID:24412560 NCBI chr13:52,652,836...52,700,909
Ensembl chr13:52,652,709...52,700,909
JBrowse link
G TGFB3 transforming growth factor beta 3 decreases expression ISO Erythromycin Estolate results in decreased expression of TGFB3 mRNA CTD PMID:24412560 NCBI chr14:75,958,097...75,983,011
Ensembl chr14:75,958,097...75,983,011
JBrowse link
G THRSP thyroid hormone responsive decreases expression ISO Erythromycin Estolate results in decreased expression of THRSP mRNA CTD PMID:17522070 NCBI chr11:78,063,861...78,068,351
Ensembl chr11:78,063,861...78,068,351
JBrowse link
G TIMP1 TIMP metallopeptidase inhibitor 1 increases expression ISO Erythromycin Estolate results in increased expression of TIMP1 mRNA CTD PMID:17522070 NCBI chr  X:47,582,436...47,586,789
Ensembl chr  X:47,582,408...47,586,789
JBrowse link
G TMCC1 transmembrane and coiled-coil domain family 1 decreases expression ISO Erythromycin Estolate results in decreased expression of TMCC1 mRNA CTD PMID:24412560 NCBI chr 3:129,647,792...129,893,711
Ensembl chr 3:129,647,792...129,893,711
JBrowse link
G TNFAIP3 TNF alpha induced protein 3 decreases expression ISO Erythromycin Estolate results in decreased expression of TNFAIP3 mRNA CTD PMID:24412560 NCBI chr 6:137,866,349...137,883,312
Ensembl chr 6:137,867,214...137,883,314
JBrowse link
G TNFRSF1A TNF receptor superfamily member 1A increases expression ISO Erythromycin Estolate results in increased expression of TNFRSF1A mRNA CTD PMID:17522070 NCBI chr12:6,328,771...6,342,076
Ensembl chr12:6,328,757...6,342,114
JBrowse link
G TP53 tumor protein p53 decreases expression ISO Erythromycin Estolate results in decreased expression of TP53 mRNA CTD PMID:17522070 NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,546
JBrowse link
G TSC22D3 TSC22 domain family member 3 decreases expression ISO Erythromycin Estolate results in decreased expression of TSC22D3 mRNA CTD PMID:24412560 NCBI chr  X:107,713,221...107,775,988
Ensembl chr  X:107,713,221...107,777,342
JBrowse link
G TTR transthyretin decreases expression ISO Erythromycin Estolate results in decreased expression of TTR mRNA CTD PMID:17522070 NCBI chr18:31,591,877...31,598,821
Ensembl chr18:31,557,009...31,598,833
JBrowse link
G TXNRD1 thioredoxin reductase 1 decreases expression ISO Erythromycin Estolate results in decreased expression of TXNRD1 mRNA CTD PMID:17522070 NCBI chr12:104,215,779...104,350,307
Ensembl chr12:104,215,779...104,350,307
JBrowse link
G UGT2A1 UDP glucuronosyltransferase family 2 member A1 complex locus increases expression ISO Erythromycin Estolate results in increased expression of UGT2A1 mRNA CTD PMID:24412560 NCBI chr 4:69,588,417...69,653,247
Ensembl chr 4:69,588,417...69,653,249
JBrowse link
G ZC3H13 zinc finger CCCH-type containing 13 increases expression ISO Erythromycin Estolate results in increased expression of ZC3H13 mRNA CTD PMID:24412560 NCBI chr13:45,954,465...46,052,746
Ensembl chr13:45,954,465...46,052,759
JBrowse link
G ZNF354A zinc finger protein 354A decreases expression ISO Erythromycin Estolate results in decreased expression of ZFP354A mRNA CTD PMID:24412560 NCBI chr 5:178,711,512...178,730,659
Ensembl chr 5:178,711,512...178,730,659
JBrowse link
G ZNF574 zinc finger protein 574 increases expression ISO Erythromycin Estolate results in increased expression of ZFP574 mRNA CTD PMID:24412560 NCBI chr19:42,068,477...42,081,552
Ensembl chr19:42,068,477...42,081,552
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 26503
    chemical entity 26483
      molecular entity 26465
        ion 19913
          anion 19267
            salt 18662
              organic salt 3467
                organic sulfate salt 226
                  2,5-diaminotoluene sulfate 0
                  4-methylaminophenol sulfate 0
                  L-canavanine sulfate 0
                  amphetamine sulfate + 0
                  atazanavir sulfate 126
                  debrisoquin sulfate 0
                  ethyl nile blue A 0
                  guanadrel sulfate 0
                  guanethidine monosulfate + 0
                  guanethidine sulfate 0
                  organoammonium sulfate salt + 116
                  quinine sulfate + 0
                  vincristine sulfate 0
                  vorapaxar sulfate 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 26503
    subatomic particle 26479
      composite particle 26479
        hadron 26479
          baryon 26479
            nucleon 26479
              atomic nucleus 26479
                atom 26479
                  main group element atom 26217
                    p-block element atom 26217
                      chalcogen 25128
                        oxygen atom 24935
                          oxygen molecular entity 24935
                            hydroxides 24126
                              oxoacid 23073
                                chalcogen oxoacid 14579
                                  sulfur oxoacid 14332
                                    sulfuric acid 8806
                                      sulfuric acid derivative 8806
                                        sulfates 8801
                                          sulfate salt 7566
                                            organic sulfate salt 226
                                              2,5-diaminotoluene sulfate 0
                                              4-methylaminophenol sulfate 0
                                              L-canavanine sulfate 0
                                              amphetamine sulfate + 0
                                              atazanavir sulfate 126
                                              debrisoquin sulfate 0
                                              ethyl nile blue A 0
                                              guanadrel sulfate 0
                                              guanethidine monosulfate + 0
                                              guanethidine sulfate 0
                                              organoammonium sulfate salt + 116
                                              quinine sulfate + 0
                                              vincristine sulfate 0
                                              vorapaxar sulfate 0
paths to the root